In a phase I-II study, 10 premenopausal patients with advanced progressive breast cancer were treated with buserelin. In 6 patients, the drug was administered at a dose of I mg q 3 subcutaneousiy (s.c.) for 7 days followed by 0.4 mg q 6 sprayed intranasally (i.n.) daily thereafter. In 3 patients, 0.3 mg q 2 s.c. was substituted for i.n. application after the 7 day loading course. In I patient, 0.4 mg q 6 daily i.n. administration alone was used. Complete remissions were observed in 2 patients with pleuropulmonal and locoregional disease, respectively, lasting 4 and 9+ months. In 3 patients with bone (2 patients) or locoregional metastases, partial remissions with a duration of 4+, 8+ and 15+ months were achieved. 3 of 6 patients with positive estrogen receptors and 2 of 2 patients with unknown estrogen receptors showed objective tumor remissions whereas in both patients with negative estrogen receptors disease progression was observed. Serial quantitation of hormones revealed a significant decrease in serum levels of estradiol after 3 weeks of treatment. Simultaneous decrease in progesterone levels at 3 weeks suggests that estrogen suppression was caused by the treatment and not by a physiological decrease due to the ovulatory cycle phase. There was no statistical correlation between hormone suppression and various doses and routes of application or between hormone levels recorded in responders and non-responders. The only side effects were tolerable menopausal symptoms. In a recent patients a local allergic reaction was recorded at the site of s.c. injection immediately after the first application of buserelin. 
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I) only ~A-plasmalevels of>t00 ng/ml show a therapeutic effect; 2) the peroral ~PA-t]mrapy leads to distinctly hi~er kPA-pl~levels with rising ~A-plasma-coacentrations. Ca accot~t of the observed individual variations the certisol-pl~level, however seems to be unsuitable for monitoring the effiency of the ~A-therapy.
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TREATME~Tf OF ADVANCED MALE BREAST CANCER WITH THE IONC--TERM LHRH AGONIST BUSERELIN C. Doberauer, N. Niederle, E. Kurschel, M. Stuschke and C.G. Schmidt
The synthetic peptide buserelim is a luteinizing hormonereleasing hormone (LHRH) analogue decreasing testosterone levels by down regulation of pituitary LF/~H receptors. Simultaneous administration of the pure antiandrogen flutamide should cause a complete blockade of androgens. Seven male patients (pts) with advanced breast cancer and no prior orchidectomy were treated with buserelin alone (6/7 pts) or in combination with flutamide (I/7 pts). Buserelin was given in dosages of 4xi00-400 ~g per day intranasally. Flutamide was applied one day before the start of buserelin treatment at a daily dose of 3x250 mg perorally. The pts ranged in age from 46-73 years (median, 57). All pts were pretreated by additive hormone therapy and/or cytostatic chemotherapy. The metastatic sites were skeleton in 6/7 pts, soft tissue in 4/7 pts and lung in 2/7 pts. Hormone receptors were found to be positive in 2/4 pts tested. In all seven pts persisting low plasma testosterone levels were associated with clinical improvement. Stable disease (SD) occurred in 6/'7 pts. I/7 pts died I month after start of therapy. The median duration of SD was 8 months (range, 4-I 5). Buserelin/flutamide combination resulted in SD lasting 4+ months, t~ain adverse effects consisted of mild hot flushes, decreased libido, impotence land transient increase of bone pain only at the beginning of buserelin treatmelqt. In conclusion, the reversible medical castration by the LHP&: analogue buserelin offers effective nontoxic palliation to male pts with advanced and pretreated breast cancer. The combination of buserelin with flutamide needs further clinical investigations.
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COMBINED CYTOTOXIC AND HIGH DOSE MEDROXYPRO-GESTERONE ACETATE TREATMENT FOR ADVANCED BREAST CANCER R.Becher, B.Hoffmann, G.Schimme3, M.Scheulen, U.Gerhold, K.HSffken and C.G.Schmidt One hundred and one patients with advanced breast cancer and measurable lesions were randomized to receive either chemotherapy with cyclophosphamide, methotrexat and 5-fluorouracil (CMF) alone or in combination with high dose medroxyprogesterone acetate (HD-MPA). Patients prior treated with CMF chemotherapy received an alternative combination with adrJa, ycin, cyclophasphamide and vincristin (ACO). The patients were stratified according to their cytotoxic pretreatment and menopausal status. At time of entry into the study, the age of patients ranged from 50 to 72 years (median age 52 years). At time of diagnosis 52 patients were premenopausal and 42 postmenopausal. HD-MPA was administered as recently reported (MPA, l. O00mg/day i.m. xlO days and 600mg/day p.o. throughout). Ninetyfour patients were evaluable for response. 7 patients (7% of cases) were lost. Treatment results showed a higher response rate in the groups with combined treatment (CMF+MPA and ACO+ MPA) as compared with those treated by chemotherapy alone (CMF and ACO). No differences, however, could be found regarding the median duration of remission as well as the survival rates.
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